REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is where they are looking to provide new chemotherapy opportunities!
Here is some more on the pre|CISION chemotherapy:
The targets for the future Affimer pre|CISION chemotherapy
Avacta has so much potential in this particular area.
The first is AVA6000 Pro-doxorubicin, Doxorubicin has been a standard of care treatment for advanced soft tissue sarcoma (ASTS) for 40 years. Treatment is currently limited to six cycles due to cumulative cardio-toxicity. However, the global market for this generic drug is still $1bn. AVA6000 Market Opportunity for three opportunities ASTS, breast and ovarian cancer, with peak sales for a safer and more efficacious form of dox in the US/EU alone is estimated to be $1.5bn pa with a 5-10% royalty to Avacta plus development milestones in the near term. This is an incredible prospect!
But then the opportunities to use the recent funds to develop the additional pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $billions per year.
Including these drugs but not limited to:
• preCISION Velcade
• preCISION Paclitaxel
• preCISION Oxaliplatin
• preCISION Gemcitabine
• preCISION Capecitabine
• preCISION PARP inhibitor
• preCISION PD-1 Inhibitor
• preCISION AKT inhibitor
• preCISION Balixafortide
The combination of Avacta’s two proprietary platforms to deliver chemotherapy and immunotherapy in a single drug molecule has two key points:
The "warhead"
Released in the tumour by the preCISION linker chemistry.
• Selected to kill tumour cells and create an inflammatory event that recruits the immune system.
• Potential for a pipeline of TMACs using different immuno-active warheads
Then the Affimer Immunotherapy:
• Supports the immune attack on the tumour by blocking the signal the tumour uses to evade the immune system.
• Potential of a pipeline of immunotherapy and targeting Affimers including bispecifics
If the trials are successful with AVA6000 the developments in these other treatments will surely be accelerated. Within 2 to 3 years we could see the results of these developments being used in Oncology clinics around world saving lives.
This area has massive potential!
Cheers Rich
The latest interview to watch can be found here with our CEO Mr Alastair Smith
https://youtu.be/cil4pGKSCWg - the key latest developments are very clear as well as potentially the most exciting prospect in the history of chemotherapy - targeted treatments with no or few side effects. The value of that development alone makes this company an incredible investment opportunity.
Cheers, Rich
The Introduction:
Avacta is a Biotech company with two operating segments, the Therapeutics operations based at Avacta’s Cambridge site (pre|CISION™ ) and the Diagnostics operations ( Affimer® ) in Wetherby.
The Expertise!
Avacta has two key areas - Affimer® technology a uniquely developed technology which is used as a diagnostic to find virus’s based on a human protein called Stefin A. The Affimer® platform is Avacta’s proprietary therapeutic platform with its intellectual property covered by several patent families.
Projects:
Affimer® technology projects with LG Chem just on licensing can be worth up to $310 million.
ADC project backed by Astra Zeneca for PBD Warheads - loaded affirmer drugs $500 million.
A joint venture in South Korea with Daewoong a leading Korean pharma company, to develop the next generation of cell and gene therapies, incorporating Affimer proteins to enhance the immune-modulatory effects. Avacta holds 45% of the business but the finance is provided by venture capitalists where the market potential is still too large to actually pinpoint as there are NDA's in place so the market information can't be shared. Huge potential!
The huge project with Affimer® technology with Moderna which again will give drug deliveries for mRNA delivery is still progressing. Huge potential!
Affimer® technology to detect Covid19 using Antigen tests the partners are Cytiva (LFD) and Adeptrix (BOMS) with distribution through 4 Mass Spectrometer suppliers (both close to production)
There are existing 5 other Affirmer evaluations progressing, 17 other projects already delivered for evaluation, and a further 7 development projects initiated!
The Expertise:
Avacta’s pre|CISION™ technology can be utilised in a drug conjugate linker or to generate chemotherapy pro-drugs that are only activated in the tumour.
When added to a chemotoxin, the pre|CISION™ substrate prevents the chemotoxin from entering cells and therefore renders it inert until the substrate is cleaved in the tumour microenvironment. Using this pro-drug approach, the systemic exposure to the chemotoxin is dramatically reduced, and the safety and therapeutic window of these powerful anti-cancer treatments are improved.
The projects:
pre|CISION™ partnerships which are looking to start with opportunities in AST, Breast and Ovarian cancer the EU/ US market potential is around $1.5 billion.
Research Opportunities for the reader:
Broker Note: https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/28b0a706-057a-4dda-bc5f-e24c2afca3cd/AvactaGroupplc_24_6_20_FINAL_BG.01.pdf
The last Presentation:
https://youtu.be/DzoxXCB4or0 - from 1hr 33min 50 seconds
Latest from Avacta: https://avacta.com/how-diagnostic-test-performance-is-measured/
A good read from a well-known researcher is found here:
https://aimchaos.files.wordpress.com/2020/06/avacta-group-update-ii-part-iii-1.pdf
Investment for 2020, it sure looks good!
Cheers Rich